Triparanol suppresses human tumor growth in vitro and in vivo

Biochemical and Biophysical Research Communications

Volumn 425, Issue 3, 2012, Pages 613-618

  Bi, Xinyu ^a   Han, Xingpeng ^b   Zhang, Fang ^c   He, Miao ^d   Zhang, Yi ^e   Zhi, Xiu Yi ^e   Zhao, Hong ^a  

^a CANCER HOSPITAL   (China)

^b TIANJIN CHEST HOSPITAL   (China)

^c TSINGHUA UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Hedgehog signaling; Triparanol; Tumor suppression

Indexed keywords

CHOLESTEROL; SONIC HEDGEHOG PROTEIN; TRIPARANOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HEDGEHOG PROTEINS; HUMANS; HYPOLIPIDEMIC AGENTS; MICE; MICE, NUDE; NEOPLASMS; TRIPARANOL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ERINACEIDAE;

EID: 84865548333     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.136     Document Type: Article

References (26)

1. Jänne P.A., Baldini E.H. Patterns of failure following surgical resection for maligant pleural mesothelioma. Thorac. Surg. Clin. 2004, 14:567-573.
2. Gonzalez-Angulo A.M., Morales-Vasquez F., Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 2007, 608:1-22.
3. Hiss D. Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J. Oncol. 2012, 737981.
4. Johnson K.A., Brown P.H. Drug development for cancer chemoprevention: focus on molecular targets. Semin. Oncol. 2010, 37:345-358.
5. Varjosalo M., Taipale J. Hedgehog: functions and mechanisms. Genes Dev. 2008, 22:2454-2472.
6. Yang L., Xie G., Fan Q., Xie J. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 2010, 29:469-481.
7. Scales S.J., de Sauvage F.J. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol. Sci. 2009, 30:303-312.
8. Ma X., Chen K., Huang S., et al. Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis 2005, 26:1698-1705.
9. Hooper J.E., Scott M.P. Communicating with Hedgehogs. Nat. Rev. Mol. Cell Biol. 2005, 6:306-317.
10. Huangfu D., Anderson K.V. Signaling from Smo to Ci/Gli: conservation and divergence of Hedgehog pathways from Drosophila to vertebrates. Development 2006, 133:3-14.
11. Osterlund T., Kogerman P. Hedgehog signalling: how to go from Smo to Ci and Gli. Trends Cell Biol. 2006, 16:176-180.
12. Ruiz i Altaba A., Sanchez P., Dahmane N. Gli and hedgehog in cancer: tumors, embryos and stem cells. Nat. Rev. Cancer 2002, 2:361-372.
13. Avigan J., Steinberg D., Vroman H.E., Thompson M.J., Mosettig E. Studies of cholesterol biosynthesis. I. The identification of desmosterol in serum and tissues of animals and man treated with MER-29. J. Biol. Chem. 1960, 235:3123-3126.
14. Cooper M.K., Porter J.A., Young K.E., Beachy P.A. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 1998, 280:1603-1607.
15. Roux C., Wolf C., Mulliez N., Gaoua W., Cormier V., Chevy F., Citadelle D. Role of cholesterol in embryonic development. Am. J. Clin. Nutr. 2000, 71:1270S-1279S.
16. Gofflot F., Hars C., Illien F., Chevy F., Wolf C., Picard J.J., Roux C. Molecular mechanisms underlying limb anomalies associated with cholesterol deficiency during gestation: implications of Hedgehog signaling. Hum. Mol. Genet. 2003, 12:1187-1198.
17. Popják G., Meenan A., Parish E.J., Nes W.D. Inhibition of cholesterol synthesis and cell growth by 24(R, S),clinph and triparanol in cultured rat hepatoma cells. J. Biol. Chem. 1989, 264:6230-6238.
18. Tiet T.D., Hopyan S., Nadesan P., Gokgoz N., Poon R., Lin A.C., Yan T., Andrulis I.L., Alman B.A., Wunder J.S. Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am. J. Pathol. 2006, 168:321-330.
19. Porter J.A., Young K.E., Beachy P.A. Cholesterol modification of hedgehog signaling proteins in animal development. Science 1996, 274:255-259.
20. Mann R.K., Beachy P.A. Cholesterol modification of proteins. Biochim. Biophys. Acta 2000, 1529:188-202.
21. Cooper M.K., Wassif C.A., Krakowiak P.A., Taipale J., Gong R., Kelley R.I., Porter F.D., Beachy P.A. A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat. Genet. 2003, 33:508-513.
22. Mann R.K., Beachy P.A. Novel lipid modifications of secreted protein signals. Annu. Rev. Biochem. 2004, 73:891-923.
23. De Smaele E., Ferretti E., Gulino A. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr. Opin. Investig. Drugs 2010, 11:707-718.
24. Low J.A., de Sauvage F.J. Clinical experience with Hedgehog pathway inhibitors. J. Clin. Oncol. 2010, 28:5321-5326.
25. Yauch R.L., Dijkgraaf G.J., Alicke B., Januario T., Ahn C.P., Holcomb T., Pujara K., Stinson J., Callahan C.A., Tang T., Bazan J.F., Kan Z., Seshagiri S., Hann C.L., Gould S.E., Low J.A., Rudin C.M., de Sauvage F.J. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009, 326:572-574.
26. Dijkgraaf G.J., Alicke B., Weinmann L., Januario T., West K., Modrusan Z., Burdick D., Goldsmith R., Robarge K., Sutherlin D., Scales S.J., Gould S.E., Yauch R.L., de Sauvage F.J. Small molecule inhibition of GDC-0449 refractory smoothened mutants and down-stream mechanisms of drug resistance. Cancer Res. 2011, 71:435-444.